Reduced Lymphocyte Transformation in Breast Cancer

Whittaker, M. G.; Rees, K. R.; Clark, C. G.

doi:10.1016/s0140-6736(71)92448-2

Cited by 165 publications

(41 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This agrees with other studies of patients with lung cancer [11,12] and other malignancies [13,14], These responses were even further depressed after therapy, but recovered to the base values six months later. Other investigators also observed radiation induced depression of in vitro responses but for longer periods of time [15,16].…”

Section: Discussionsupporting

confidence: 93%

Phytohemagglutinin Stimulation of Lymphocytes in Lung Cancer Patients

Kerman¹,

Stefani²

1977

Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Phytohemagglutinin Stimulation of Lymphocytes in Lung Cancer Patients

Kerman¹,

Stefani²

1977

Oncology

View full text Add to dashboard Cite

show abstract

“…Impaired cellular and humoral immune responses have been described in various malignant diseases [10][11][12], The importance of lymphocyte reactivity and the rela tionship between T lymphocyte subsets in cancer patients has been shown by several investigators [13][14][15]. Early stu dies by O'Toole et al [16] demonstrated a correlation be tween lymphocyte reactivity against bladder tumor cells and clinical stage in 54 patients with bladder carcinoma.…”

Section: Discussionmentioning

confidence: 99%

T Lymphocyte Subsets and Function in the Peripheral Blood of Patients with Urological Cancer

Kaver¹,

Pecht²,

Trainin³

et al. 1992

Oncology

View full text Add to dashboard Cite

The phenotypic distribution and immune reactivity of T lymphocyte sub-populations from peripheral blood of 50 patients with urological cancer were determined. Included were 36 patients with bladder transitional cell carcinoma, 7 patients with renal cell carcinoma and 7 patients with prostatic carcinoma. Thirty-eight age-matched patients with benign urological disease served as controls. A depression in immune competence was found in the group of male patients with infiltrating bladder cancer. In more than 50% of the patients with infiltrating bladder carcinoma, the T helper (CD4) subset was reduced with a concomitant inversion in the CD4/CD8 ratio and impairment in the T cell function as determined by the ability to proliferate upon phyto-hemagglutinin and concanavalin stimulation. Patients with superficial bladder carcinoma, as well as those with renal cell carcinoma had an immune profile similar to that of the control group. The group of patients with prostatic carcinoma had higher mean CD4/CD8 ratios than the control group, resulting from decreased suppressor/cytotoxic cells. Our results have indicated that the characterization of T cell subset and lymphocyte activity correlated well with the histopathologic stage of patients with bladder carcinoma. Thus, the determination of the CD4/CD8 ratio may prove a valuable method for monitoring patients with bladder carcinoma, in addition to serial urine cytology, random urothelial biopsies and flow cytometry.

show abstract

“…These donors had a 50 % chance of developing recurrence or dying of their disease. Others have reported that serum factors had an immune suppression effect in carcinoma of the breast (Whittaker et al, 1971), colorectal cancer (Guillou and Giles, 1973), and melanoma (Cochran et al, 1976 Pryce, 1966), stomach (Black et al, 1971) and colon (Murray et al, 1975). The findings in this study confirm these results.…”

Section: Discussionmentioning

confidence: 99%

Survival and the immune response in patients with carcinoma of the colorectum.

House¹,

Watt²

1979

Gut

View full text Add to dashboard Cite

(Slaney, 1971;Gill and Morris, 1978). In addition, patients with 'early' lesions, Dukes stage A or B, and those who can be offered an anterior instead of an abdominoperineal resection enjoy a survival advantage (Gill and Morris, 1978).Despite these clinical prognostic observations, the final denominator determining survival is the host tumour interaction. This response is best seen in the tumour invasion profile, which can be used to predict the likely disease progression (Montessori and Donald, 1978). This profile is possibly an expression of tumour factors like their ability to secrete mucus or their histological grade (Grinnell, 1939) and the host immunological reaction to the tumour. Previously we have examined the host immune response to carcinoma of the colon by measuring the lymphocyte invasion of the tumour specimen (Watt and House, 1978) and the leucocyte migration inhibition response of patient's leucocytes to their tumour (House et al., 1975). The present study extends these observations. Received for publication 26 April 1979 Methods PATIENTSThe subject under study included 107 individuals with colorectal carcinoma on whom a series of 340 leucocyte migration inhibition observations were made. The tumors of these same patients were examined for invasion by lymphocytes. Review of these 107 patients showed there were 29 right, 45 left colonic, and 33 rectal tumours and, among these, 29 were stages Dukes A, 37 Dukes B, and 41 Dukes C. The observation time was from two to six years or until death. The details relating to patient follow-up were collected retrospectively from hospital records, general practitioners, and the Registry of Deaths in Western Australia. The patients' differential white blood cell counts were not regularly available to correlate with the in vitro assays.Three hundred and forty leucocyte migration inhibition assays were also performed on a control group of 150 patients who were attending the hospital for disease which was not neoplastic or immunological in nature. They were selected to match the patients for blood group, age, severity of operative trauma, and time after surgery at which the tests were performed. 868

show abstract

Reduced Lymphocyte Transformation in Breast Cancer

Cited by 165 publications

References 7 publications

Phytohemagglutinin Stimulation of Lymphocytes in Lung Cancer Patients

Phytohemagglutinin Stimulation of Lymphocytes in Lung Cancer Patients

T Lymphocyte Subsets and Function in the Peripheral Blood of Patients with Urological Cancer

Survival and the immune response in patients with carcinoma of the colorectum.

Contact Info

Product

Resources

About